Monica L Hand, PA
Physician Assistant · Kansas City
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 7
- Since medical school
- 9 years
- Graduated 2017
Offices
7 locations · Kansas University Physicians Inc · 1,809 clinicians in this group
Hospitals listed: University of Kansas Hospital. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Monica L Hand’s office to ask if they take your plan before you enroll.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- University of Kansas HospitalKansas City, KSAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of The University of Kansas Health System, which runs 5 hospitalsHome of University of Kansas Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 84% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — SSI - Colon Surgery: 1.749, Oct 2024 – Sep 2025Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.189, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.426, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.554, Oct 2024 – Sep 2025Better than the national rate — Rate of emergency department (ED) visits for patients receiving outpatient chemotherapy: 4.4 (3.7 to 5.2) · 2,295 cases, Jan 2024 – Dec 2024Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 0.9) · 2,936 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for University of Kansas Hospital
Behind the star rating — Deaths: 4 better, 3 the same, 1 worse of 8 measures. Safety: 4 better, 3 the same, 0 worse of 7 measures. Readmissions: 5 better, 3 the same, 2 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| SSI - Colon SurgeryInfections | 1.749 | Worse | Oct 2024 – Sep 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.189 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.426 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.554 | Better | Oct 2024 – Sep 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.4 (3.7 to 5.2) · 2,295 cases | Better | Jan 2024 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.7 to 0.9) · 2,936 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.2 (0.58 to 1.83) · 5,459 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.97 (0.82 to 1.12) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 150.23 (121.85 to 178.61) · 461 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.4 · 180 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.7 · 159 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.3 · 151 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 7.4 · 872 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.1 · 555 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 14.3 · 588 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.4 · 7,273 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.17 (0.02 to 0.32) · 18,998 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.05 to 0.36) · 20,486 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.25 (2.08 to 4.43) · 6,689 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.62 (0.68 to 2.56) · 3,621 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.88 (1.99 to 3.76) · 5,793 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.44 (4.79 to 10.09) · 3,445 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.77 (4.02 to 7.52) · 3,539 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.16 (0.02 to 2.3) · 1,773 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.72 (0.4 to 1.05) · 17,130 cases | No different | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.586 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 1.135 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13 · 246 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.2 · 1,551 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -39.2 · 191 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -25.2 · 1,034 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 14.1 · 608 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 832 cases | None | Jul 2023 – Jun 2025 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.2 (10.1 to 12.5) · 2,295 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 8.4 · 169 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.4 · 360 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12 (9.3 to 15.3) · 1,404 cases | No different | Jan 2022 – Dec 2024 |
What patients said (3,109 patients answered, 23% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 4 |
| Recommend hospital | 5 |
| Room was "always" clean | 73% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 64% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 80% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 76% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 89% |
| "Always" quiet at night | 60% |
| "YES", patients would definitely recommend the hospital | 84% |
| Staff "always" explained possible side effects | 51% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$24,480
Medicare paid this office $24,480 for 265 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Short return visit (20+ min) | 109 | $6,269 | $42 |
| Return visit (30+ min) | 61 | $4,213 | $59 |
| Short return visit (20+ min) | 48 | $2,370 | $39 |
| Short return visit | 59 | $1,822 | $23 |
| Long return visit (40+ min) | 13 | $1,184 | $85 |
See all 15 services
| Short return visit (20+ min) | 109 | $6,269 | $42 |
| Return visit (30+ min) | 61 | $4,213 | $59 |
| Short return visit (20+ min) | 48 | $2,370 | $39 |
| Short return visit | 59 | $1,822 | $23 |
| Long return visit (40+ min) | 13 | $1,184 | $85 |
| Return visit (30+ min) | 16 | $1,019 | $57 |
| Telephone medical discussion with physician, 21-30 minutes | 12 | $948 | $73 |
| Simple bladder irrigation and/or instillation | 19 | $888 | $19 |
| Short return visit | 27 | $808 | $22 |
| Fitting and insertion of vaginal support device | 13 | $509 | $34 |
| Insertion of temporary bladder tube | 21 | $432 | $18 |
| Fitting and insertion of vaginal support device | 12 | $384 | $30 |
| Insertion of temporary bladder tube | 14 | $214 | $14 |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 13 | $100 | $7 |
| Urinalysis, manual test | 12 | $48 | $3 |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Simple bladder irrigation and/or instillation | 167 | 101 | 65 | 38 | 21 | 46 |
| Insertion of temporary bladder tube | 62 | 51 | 82 | 59 | 52 | 39 |
| Fitting and insertion of vaginal support device | 31 | 27 | – | 19 | 14 | 28 |
| Ultrasound measurement of bladder capacity after voiding | 58 | 11 | – | – | – | – |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
265 Original Medicare patients in 2024. Average age 75 · Women 100% · Health risk score 1.18. At or below the middle of the specialty; the typical physician assistant clinician is at 1.31.
Conditions among them: High blood pressure 69% · Coronary heart disease 30% · Depression 27% · Diabetes 22% · Cancer 20% · Chronic kidney disease 15% · Heart failure 14% · Atrial fibrillation 13% · COPD 12% · Stroke 8% · Dementia 6%.
The office billed $124,817, Medicare allowed $33,924 and paid $24,480; for 682 services of 24 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 265 | 682 | 75 | 1.18 | $124,817 | $24,480 |
| 2023 | 186 | 467 | 75 | 1.20 | $83,298 | $17,288 |
| 2022 | 233 | 633 | 74 | 1.13 | $106,470 | $21,628 |
| 2021 | 223 | 728 | 73 | 1.26 | $116,249 | $22,854 |
| 2020 | 202 | 2,233 | 72 | 1.18 | $141,391 | $21,834 |
| 2019 | 185 | 3,478 | 73 | 1.23 | $198,531 | $31,252 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 11 services
| Short return visit (20+ min) | 74 | $3,980 | $39 |
| Return visit (30+ min) | 49 | $3,602 | $59 |
| Long return visit (40+ min) | 12 | $1,261 | $97 |
| Short return visit (20+ min) | 23 | $1,026 | $33 |
| Return visit (30+ min) | 13 | $877 | $63 |
| Short return visit | 37 | $762 | $18 |
| Insertion of temporary bladder tube | 30 | $588 | $16 |
| Short return visit | 21 | $528 | $20 |
| Fitting and insertion of vaginal support device | 12 | $444 | $32 |
| Simple bladder irrigation and/or instillation | 11 | $365 | $17 |
| Insertion of temporary bladder tube | 14 | $211 | $14 |
2022: 11 services
| Short return visit (20+ min) | 96 | $5,455 | $40 |
| Return visit (30+ min) | 46 | $3,419 | $59 |
| Short return visit (20+ min) | 38 | $2,170 | $41 |
| Short return visit | 59 | $1,928 | $21 |
| Return visit (30+ min) | 17 | $1,031 | $54 |
| Insertion of temporary bladder tube | 37 | $808 | $18 |
| Short return visit | 29 | $749 | $20 |
| Simple bladder irrigation and/or instillation | 12 | $587 | $15 |
| Fitting and insertion of vaginal support device | 18 | $574 | $30 |
| New patient visit (30+ min) | 11 | $550 | $50 |
| Insertion of temporary bladder tube | 13 | $198 | $14 |
2021: 11 services
| Short return visit (20+ min) | 87 | $5,705 | $39 |
| Return visit (30+ min) | 54 | $3,559 | $62 |
| Short return visit | 83 | $2,751 | $21 |
| Simple bladder irrigation and/or instillation | 17 | $1,251 | $19 |
| Short return visit (20+ min) | 24 | $1,236 | $41 |
| New patient visit (45+ min) | 17 | $1,209 | $71 |
| Short return visit | 32 | $928 | $18 |
| Return visit (30+ min) | 14 | $919 | $61 |
| Insertion of temporary bladder tube | 42 | $898 | $15 |
| Telephone medical discussion with physician, 21-30 minutes | 11 | $704 | $64 |
| Insertion of temporary bladder tube | 22 | $349 | $15 |
2020: 17 services
| Short return visit (20+ min) | 60 | $3,298 | $33 |
| Simple bladder irrigation and/or instillation | 20 | $2,637 | $26 |
| Return visit (30+ min) | 35 | $2,265 | $53 |
| Short return visit (20+ min) | 49 | $2,011 | $30 |
| Return visit (30+ min) | 28 | $1,345 | $43 |
| New patient visit (45+ min) | 19 | $1,261 | $66 |
| New patient visit (45+ min) | 17 | $1,165 | $69 |
| Telephone medical discussion with physician, 21-30 minutes | 19 | $1,143 | $52 |
| Short return visit | 35 | $950 | $17 |
| Injection, hydrocortisone sodium succinate, up to 100 mg | 13 | $606 | None |
| Insertion of temporary bladder tube | 24 | $493 | $18 |
| Fitting and insertion of vaginal support device | 12 | $435 | $29 |
| Short return visit | 20 | $388 | $14 |
| Insertion of temporary bladder tube | 20 | $376 | $16 |
| Fitting and insertion of vaginal support device | 12 | $302 | $25 |
| Injection, heparin sodium, per 1000 units | 13 | $226 | None |
| Ultrasound measurement of bladder capacity after voiding | 11 | $52 | $5 |
2019: 15 services
| Simple bladder irrigation and/or instillation | 40 | $7,567 | $45 |
| Short return visit (20+ min) | 69 | $4,187 | $38 |
| New patient visit (45+ min) | 41 | $3,778 | $92 |
| Return visit (30+ min) | 46 | $2,749 | $53 |
| Injection, hydrocortisone sodium succinate, up to 100 mg | 26 | $1,828 | None |
| Insertion of temporary bladder tube | 43 | $1,627 | $26 |
| Fitting and insertion of vaginal support device | 25 | $1,011 | $33 |
| Pessary, reusable, non rubber, any type | 21 | $925 | $37 |
| Short return visit | 26 | $884 | $25 |
| Return visit (30+ min) | 16 | $837 | $49 |
| Short return visit (20+ min) | 14 | $463 | $33 |
| Ultrasound measurement of bladder capacity after voiding | 56 | $450 | $8 |
| Injection, heparin sodium, per 1000 units | 22 | $398 | None |
| Urinalysis, manual test | 32 | $130 | $3 |
| Automated urinalysis test | 16 | $41 | $2 |
Medicaid work
$7 in 2021
Medicaid paid $7 for 15 billed services this clinician did in 2021, up to 15 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Hospital outpatient clinic visit for assessment and management of a patient | 15 | $7 |
| 2021 | 15 | 1 | 15 | $7 |
Drugs they prescribed that Part D paid
$118,639
Pharmacies billed $118,639 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 744) in 2024. At or below the middle of the specialty; the typical physician assistant clinician is at 1%.
561 generic and 183 brand-name prescriptions · $118,639 in drug cost · 326 antibiotic prescriptions to 191 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Gemtesa | 75 | $47,924 | $639 |
| Myrbetriq | 69 | $47,172 | $684 |
| Estradiol | 89 | $6,012 | $68 |
| Methenamine Hippurate | 29 | $3,273 | $113 |
| Nitrofurantoin Mono-Macro | 68 | $825 | $12 |
See all 16 drugs
| Gemtesa | 75 | $47,924 | $639 |
| Myrbetriq | 69 | $47,172 | $684 |
| Estradiol | 89 | $6,012 | $68 |
| Methenamine Hippurate | 29 | $3,273 | $113 |
| Nitrofurantoin Mono-Macro | 68 | $825 | $12 |
| Cefdinir | 37 | $511 | $14 |
| Clobetasol Propionate | 16 | $423 | $26 |
| Cephalexin | 48 | $320 | $7 |
| Fluconazole | 37 | $261 | $7 |
| Sulfamethoxazole-Trimethoprim | 65 | $168 | $3 |
| Triamcinolone Acetonide | 15 | $99 | $7 |
| Amoxicillin-Clavulanate Potass | 15 | $88 | $6 |
| Ciprofloxacin | 18 | $85 | $5 |
| Amoxicillin | 32 | $83 | $3 |
| Metronidazole | 14 | $48 | $3 |
| Levofloxacin | 14 | $38 | $3 |
Year by year
| 2024 | 744 | 290 | 0% (0) | 25% | $118,639 |
| 2023 | 489 | 188 | 0% (0) | 31% | $116,372 |
| 2022 | 447 | 166 | 0% (0) | 25% | $103,051 |
| 2021 | 507 | 170 | None | 22% | $121,316 |
| 2020 | 406 | 153 | 0% (0) | 22% | $83,242 |
| 2019 | 266 | 126 | 0% (0) | None | $45,206 |
| 2018 | 15 | None | 0% (0) | None | $3,347 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 11 drugs
| Myrbetriq | 100 | $75,281 | $753 |
| Gemtesa | 13 | $13,952 | $1,073 |
| Estradiol | 81 | $8,292 | $102 |
| Methenamine Hippurate | 13 | $2,489 | $191 |
| Nitrofurantoin Mono-Macro | 30 | $569 | $19 |
| Trospium Chloride | 12 | $526 | $44 |
| Cefdinir | 15 | $474 | $32 |
| Clobetasol Propionate | 12 | $299 | $25 |
| Cephalexin | 20 | $200 | $10 |
| Sulfamethoxazole-Trimethoprim | 38 | $193 | $5 |
| Amoxicillin | 18 | $58 | $3 |
2022: 13 drugs
| Myrbetriq | 72 | $60,307 | $838 |
| Estradiol | 90 | $9,112 | $101 |
| Gemtesa | 12 | $7,502 | $625 |
| Methenamine Hippurate | 31 | $5,629 | $182 |
| Trospium Chloride Er | 11 | $1,994 | $181 |
| Solifenacin | 17 | $1,068 | $63 |
| Trospium Chloride | 23 | $1,059 | $46 |
| Clobetasol Propionate | 14 | $593 | $42 |
| Nitrofurantoin Mono-Macro | 11 | $235 | $21 |
| Cefdinir | 12 | $182 | $15 |
| Triamcinolone Acetonide | 15 | $110 | $7 |
| Fluconazole | 14 | $58 | $4 |
| Sulfamethoxazole-Trimethoprim | 13 | $42 | $3 |
2021: 13 drugs
| Myrbetriq | 63 | $57,885 | $919 |
| Elmiron | 16 | $20,511 | $1,282 |
| Estradiol | 104 | $13,554 | $130 |
| Methenamine Hippurate | 22 | $2,934 | $133 |
| Trospium Chloride Er | 12 | $2,290 | $191 |
| Solifenacin | 23 | $2,102 | $91 |
| Trospium Chloride | 15 | $1,846 | $123 |
| Yuvafem | 13 | $1,843 | $142 |
| Clobetasol Propionate | 22 | $581 | $26 |
| Nitrofurantoin Mono-Macro | 13 | $353 | $27 |
| Amoxicillin-Clavulanate Potass | 15 | $207 | $14 |
| Fluconazole | 24 | $201 | $8 |
| Cephalexin | 19 | $156 | $8 |
2020: 10 drugs
| Myrbetriq | 36 | $25,959 | $721 |
| Elmiron | 18 | $19,174 | $1,065 |
| Estradiol | 86 | $13,784 | $160 |
| Oxybutynin Chloride Er | 21 | $2,031 | $97 |
| Methenamine Hippurate | 18 | $1,715 | $95 |
| Solifenacin | 12 | $1,374 | $114 |
| Clobetasol Propionate | 25 | $1,136 | $45 |
| Cephalexin | 19 | $240 | $13 |
| Amoxicillin-Clavulanate Potass | 17 | $145 | $9 |
| Sulfamethoxazole-Trimethoprim | 22 | $69 | $3 |
2019: 8 drugs
| Myrbetriq | 22 | $12,647 | $575 |
| Estradiol | 55 | $9,759 | $177 |
| Oxybutynin Chloride Er | 13 | $1,024 | $79 |
| Clobetasol Propionate | 13 | $665 | $51 |
| Levofloxacin | 13 | $125 | $10 |
| Amoxicillin-Clavulanate Potass | 12 | $123 | $10 |
| Fluconazole | 12 | $72 | $6 |
| Sulfamethoxazole-Trimethoprim | 12 | $39 | $3 |
Money from drug and device companies
$41 in 2025
| 2025 | 2 | 2 | None | $41 |
| 2024 | 3 | 5 | None | $88 |
| 2023 | 2 | 2 | None | $37 |
| 2022 | 2 | 2 | None | $36 |
| 2021 | 6 | 11 | None | $233 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Genentech USA | Xolair | $24 | 1 payment
|
| Abbvie | Skyrizi | $17 | 1 payment
|
See all 2 published payments
| Abbvie | Meals · 2025-09-29 | Skyrizi | $17 |
| Genentech USA | Meals · 2025-05-30 | Xolair | $24 |
See earlier years (2024, 2023, 2022, 2021)
2024: $88
| Abbvie | Botox | $50 | 3 payments
|
| AstraZeneca Pharmaceuticals LP | Fasenra | $21 | 1 payment
|
| Regeneron Healthcare Solutions | Dupixent | $18 | 1 payment
|
2023: $37
| Salix Pharmaceuticals a division of Bausch Health US | Trulance | $23 | 1 payment
|
| Merck Sharp & Dohme | Dificid | $14 | 1 payment
|
2022: $36
| Janssen Biotech | Stelara | $22 | 1 payment
|
| Ironwood Pharmaceuticals | Linzess | $14 | 1 payment
|
2021: $233
| AbbVie | None | $86 | 1 payment
|
| Allergan | Botox | $48 | 4 payments
|
| Bayer HealthCare Pharmaceuticals | Kyleena | $39 | 2 payments
|
| Antares Pharma | Xyosted | $31 | 2 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Trulance | $16 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $13 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 91.9 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1366961203
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Physician assistant (363A00000X)
- Mailing address
- 1645 W School St Apt 322, Chicago, IL, 60657
- NPI first listed
- 2017-09-12
- NPI last updated
- 2018-03-17
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 14552 John Humphrey Dr, Orland Park, IL, 60462